PT946731E - Estirpes de vih não m e não o, os seus fragmentos e aplicações - Google Patents

Estirpes de vih não m e não o, os seus fragmentos e aplicações Download PDF

Info

Publication number
PT946731E
PT946731E PT97950245T PT97950245T PT946731E PT 946731 E PT946731 E PT 946731E PT 97950245 T PT97950245 T PT 97950245T PT 97950245 T PT97950245 T PT 97950245T PT 946731 E PT946731 E PT 946731E
Authority
PT
Portugal
Prior art keywords
strain
ybf30
hiv
regard
group
Prior art date
Application number
PT97950245T
Other languages
English (en)
Inventor
Phil Mauclere
Ibtissam Loussert-Ajaka
Francois Simon
Sentob Saragosti
Francoise Barre-Sinoussi
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris filed Critical Pasteur Institut
Publication of PT946731E publication Critical patent/PT946731E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
PT97950245T 1996-12-09 1997-12-08 Estirpes de vih não m e não o, os seus fragmentos e aplicações PT946731E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615087A FR2756843B1 (fr) 1996-12-09 1996-12-09 Souches de vih-1 non-m non-o, fragments et applications

Publications (1)

Publication Number Publication Date
PT946731E true PT946731E (pt) 2009-05-14

Family

ID=9498464

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97950245T PT946731E (pt) 1996-12-09 1997-12-08 Estirpes de vih não m e não o, os seus fragmentos e aplicações

Country Status (14)

Country Link
US (4) US6509018B1 (pt)
EP (1) EP0946731B1 (pt)
JP (1) JP2000515768A (pt)
CN (1) CN1244896B (pt)
AT (1) ATE422544T1 (pt)
AU (1) AU737857B2 (pt)
BR (1) BRPI9713891B8 (pt)
CA (1) CA2274490C (pt)
DE (1) DE69739251D1 (pt)
DK (1) DK0946731T3 (pt)
ES (1) ES2323604T3 (pt)
FR (1) FR2756843B1 (pt)
PT (1) PT946731E (pt)
WO (1) WO1998026075A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
DE60041489D1 (de) * 1999-07-09 2009-03-19 Gen Probe Inc Nachweis von hiv-1 durch amplifizierung von nukleinsäuren
DE19936003A1 (de) * 1999-08-03 2001-02-15 Dade Behring Marburg Gmbh Lentivirus aus der Gruppe der Immunschwächeviren der Drillaffen(mandrillus leucophaeus) und ihre Verwendung
WO2004092724A2 (en) * 2003-04-11 2004-10-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Multiple antigenic peptide assay for detection of hiv or siv type retroviruses
WO2006018289A1 (en) * 2004-08-17 2006-02-23 Institut Gustave Roussy Mutated hiv nef for modulating immunity
WO2007084568A2 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
RU2355763C2 (ru) * 2006-09-13 2009-05-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот
JP2010521156A (ja) * 2007-03-16 2010-06-24 ４５４ ライフ サイエンシーズ コーポレイション Ｈｉｖ薬物耐性バリアントの検出のためのシステムおよび方法
US20090258342A1 (en) * 2008-04-09 2009-10-15 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1
US9650668B2 (en) 2008-09-03 2017-05-16 Nabsys 2.0 Llc Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
EP2640849B1 (en) 2010-11-16 2016-04-06 Nabsys 2.0 LLC Methods for sequencing a biomolecule by detecting relative positions of hybridized probes
WO2012109574A2 (en) 2011-02-11 2012-08-16 Nabsys, Inc. Assay methods using dna binding proteins
US9914966B1 (en) 2012-12-20 2018-03-13 Nabsys 2.0 Llc Apparatus and methods for analysis of biomolecules using high frequency alternating current excitation
EP2956550B1 (en) 2013-01-18 2020-04-08 Nabsys 2.0 LLC Enhanced probe binding

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122005000039I1 (de) * 1984-10-18 2006-02-23 Pasteur Institut DNS-Fragmente des GAG-Gens von LAV
JP2767078B2 (ja) * 1990-10-17 1998-06-18 アメリカ合衆国 Ｈｉｖ―１の分子クローンとその使用法
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
US5945301A (en) * 1995-09-29 1999-08-31 Chugai Seiyaku Kabushiki Kaisha Kinase in TGF-β family signal transduction system
US5994123A (en) * 1996-08-09 1999-11-30 Regents Of University Of Minnesota Sugarcane bacilliform virus promoter

Also Published As

Publication number Publication date
JP2000515768A (ja) 2000-11-28
US20070190524A1 (en) 2007-08-16
ES2323604T3 (es) 2009-07-21
CA2274490C (fr) 2013-02-12
CA2274490A1 (fr) 1998-06-18
US20100184014A1 (en) 2010-07-22
US7030234B2 (en) 2006-04-18
BRPI9713891B1 (pt) 2015-08-18
CN1244896B (zh) 2011-06-22
DE69739251D1 (de) 2009-03-26
US7534877B2 (en) 2009-05-19
US8227185B2 (en) 2012-07-24
US6509018B1 (en) 2003-01-21
BRPI9713891B8 (pt) 2021-07-06
BRPI9713891A (pt) 2000-02-29
WO1998026075A1 (fr) 1998-06-18
US20030157660A1 (en) 2003-08-21
FR2756843A1 (fr) 1998-06-12
AU737857B2 (en) 2001-08-30
DK0946731T3 (da) 2009-06-22
CN1244896A (zh) 2000-02-16
AU5327298A (en) 1998-07-03
EP0946731B1 (fr) 2009-02-11
EP0946731A1 (fr) 1999-10-06
FR2756843B1 (fr) 1999-01-22
ATE422544T1 (de) 2009-02-15

Similar Documents

Publication Publication Date Title
PT946731E (pt) Estirpes de vih não m e não o, os seus fragmentos e aplicações
AU3762889A (en) Hiv-3 retrovirus and its use
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
EP0752887A4 (en) RECOMBINANT IMMUNE WEAKNESS POX VIRUS
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
AU4712397A (en) Lentiviral vectors
EP1372710A4 (en) MVA-EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES
IL112636A0 (en) Non-pathogenic strains of hiv-1
CA2328404A1 (en) Novel lentiviral packaging cells
FR2731013B1 (fr) Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
Nakamura et al. Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation
EP0404625A3 (fr) Séquences oligonucléotidiques pour l'amplification du génome des rétrovirus du type HIV-2 et SIV, et leurs applications au diagnostic in-vitro des infections dûes à ces virus
IGARASHI et al. Isolation and genomic analysis of human T lymphotropic virus type II from Ghana
Whitcomb et al. The sequence of human immunodeficiency virus type 2 circle junction suggests that integration protein cleaves the ends of linear DNA asymmetrically
DeVICO et al. High prevalence of serum antibodies to reverse transcriptase in HIV-1-infected individuals
Velarde-Dunois et al. Molecular characterization of human immunodeficiency virus type 1-infected individuals from Bolivia reveals the presence of two distinct genetic subtypes B and F
Artenstein et al. Sequence Note: Sequences and Phylogenetic Analysis of the nef Gene from Thai Subjects Harboring Subtype E HIV-1
SHEREFA et al. Sequence Note: Full-Length Sequence of Human Immunodeficiency Virus Type 1 Subtype A, Recombined with Subtype C in the env V3 Domain
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.
WO2022035860A3 (en) Replication-competent adenovirus type 4-hiv env vaccines and their use